Clinical Trial Update: Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety, tolerability, PK and PD study of Neu-120 for Levodopa-induced Dyskinesia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Levodopa-induced Dyskinesia

Drugs mentioned

• Neu-120

Snippet

Sponsor: Neurim Pharmaceuticals Ltd. | Conditions: Levodopa-induced Dyskinesia | Phase 1, Phase 2 | Status: TERMINATED